ABC News reported on December 20 that the European Union authorized the use of the Novavax vaccine against COVID-19.
Manufactured in the United States, Novavax's two-dose vaccine will be the fifth coronavirus vaccine to be approved by the EU.
The European Union has ordered around 100 million doses of the Novavax vaccine.
Research by the European Medicines Agency concluded that "the data on the vaccine were robust and met the EU criteria for efficacy, safety and quality."
In a study of 30,000 citizens of the United States and Mexico, the vaccine was 90% effective against pre-Omicron variants, the most recent variant of the coronavirus.
"We delivered this vaccine to the EU at a critical time when we believe that the choice between vaccines will lead to increased immunization," says Stanley C. Erck, CEO of Novavax.
